MICHAEL CASTAGNA, PHARM.D.

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

MANNKIND CORP

Filing Date Source Excerpt
2017-11-17 Includes 2,744 shares which Dr. Castagna has the right to acquire within 60 days of October 30, 2017 pursuant to the exercise of outstanding options.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22